OptiBiotix Health PLC Market launch for LPLDL® capsules in Germany (0645M)
July 26 2017 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0645M
OptiBiotix Health PLC
26 July 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Market launch for LP(LDL) (R) capsules in Germany
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH")
have achieved product registration of LP(LDL) (R) capsules at IFA
GmbH and "Bundesamt für Lebensmittelsicherheit und
Verbraucherschutz (BVL)" and commenced commercial sales to
pharmacies in Germany on 24 July 2017.
This announcement follows on from the three year supply
agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15
June 2017. HLH will market capsules containing LP(LDL) (R) under
the brand name Lactobact(R) LDL-Control and promote them directly
to the pharmacy market in Germany, as well as to consumers on their
online platform. Sales revenues are difficult to estimate in this
new and developing market but are likely to be in the low to mid
six figure in the near term growing as HLH builds market
presence.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
see the first sales of our LP(LDL) (R) strain in products available
to consumers in Germany. We hope this will be the first of many
product launches of multiple formulations and presentations of
LP(LDL) (R) as the active component in a wide range of
pharmaceutical and consumer products around the world. HLH have an
international reputation for providing high quality and
scientifically validated products and are one of Europe's leading
suppliers of probiotics to the pharmacy market. Establishing early
sales of LP(LDL) (R) to pharmacies with HLH helps substantiate the
credibility in the science behind LP(LDL) (R) to build the brand
and acceptance in the larger consumer healthcare markets."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke / Abigail Wayne (Corporate
Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVAVRBVABUAR
(END) Dow Jones Newswires
July 26, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024